Tango Therapeutics Reports Promising Results for TNG462 in Cancer Treatment Advancements
- Tango Therapeutics reports a 43% response rate for TNG462 in cholangiocarcinoma, moving toward full development.
- The company is introducing TNG456, a next-generation PRMT5 inhibitor aimed at glioblastoma and other solid tumors.
- Tango aims to enhance TNG462's efficacy through strategic partnerships and plans further clinical trials starting in 2025.
Tango Therapeutics Advances PRMT5 Program with Promising Clinical Results
Tango Therapeutics, Inc., a clinical-stage biotechnology company specializing in precision cancer therapies, announces significant progress in its PRMT5 development program, particularly with its lead candidate, TNG462. Recent results from the TNG462 phase 1/2 clinical trial reveal a notable overall response rate (ORR) of 43% in patients with cholangiocarcinoma, alongside favorable activity and tolerability profiles. This momentum drives Tango to transition TNG462 into full development, with plans to initiate further clinical evaluations as a monotherapy and in combination with other therapeutic agents in the first half of 2025. The company aims to expand TNG462's application to treat a variety of solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer, thereby positioning it as a potential best-in-class MTA-cooperative PRMT5 inhibitor.
In tandem with its advancements in TNG462, Tango Therapeutics also introduces TNG456, a next-generation brain-penetrant PRMT5 inhibitor designed to improve potency and selectivity for glioblastoma (GBM) and other solid tumors. The decision to halt enrollment in the TNG908 trial reflects the company's strategic shift toward maximizing resources for TNG462 and TNG456, particularly given TNG908's inadequate pharmacokinetic exposure for effective glioblastoma treatment despite its clinical activity in non-CNS solid tumors. Tango’s commitment to addressing the unmet needs of patients with MTAP-deleted cancers remains unwavering, as the company seeks to broaden its impact within the oncology landscape.
To bolster its clinical development efforts, Tango Therapeutics announces the appointment of Dr. Maeve Waldron-Lynch as Senior Vice President and Head of Clinical Development. Dr. Waldron-Lynch brings extensive oncology experience, which will be vital in guiding TNG462 toward potential registration trials. In a strategic partnership, Tango also collaborates with Revolution Medicines to conduct combination trials involving RAS(ON) tri-complex inhibitors, further enhancing the potential efficacy of TNG462. As the next clinical updates for TNG462 are anticipated in 2025, Tango Therapeutics is on a promising trajectory to transform cancer treatment through its innovative PRMT5 inhibitors.
In addition to its focus on TNG462 and TNG456, Tango Therapeutics continues to evaluate the clinical landscape for its other compounds. The company’s recent financial results highlight the ongoing commitment to advancing precision cancer therapies and meeting patient needs. Tango’s strategic direction and pipeline developments underscore its role as a driving force in the evolving field of oncology, aiming to deliver effective solutions for challenging cancer types.